GENERAL, O. Reg. 201/96

Section 11

Cite as GENERAL, O. Reg. 201/96, s. 11 · current to November 11, 2026 · consolidated from July 1, 2026 · read from e-Laws on November 16, 2026

The text

(1) A strength and dosage form of a product that has been submitted for designation as an interchangeable product under the Drug Interchangeability and Dispensing Fee Act shall not be designated as a listed drug product unless the manufacturer submits the information required under section 6 of Regulation 935 of the Revised Regulations of Ontario, 1990 (General) made under that Act and the following conditions are met: 1. If the original product is a listed drug product, the drug benefit price of the product proposed to the executive officer under clause 6 (1) (d) of Regulation 935 of the Revised Regulations of Ontario, 1990 must be, i. less than or equal to 25 per cent of the drug benefit price of the original product as set out in the Formulary, A. on the date the product is first proposed for designation as a listed drug product, if no other product has been designated as interchangeable with the original product, or B. in all other cases, on the date when the first product became designated as interchangeable with the original product, or ii. if the drug benefit price of the original product has been reduced by more than 20 per cent in the 24-month period before the date on which the product is proposed for designation as a listed drug product, less than or equal to 25 per cent of the drug benefit price of the original product as set out in the Formulary immediately before the drug benefit price of the original product was first reduced. 2. If the original product was but is no longer a listed drug product, the drug benefit price of the product proposed to the executive officer under clause 6 (1) (d) of Regulation 935 of the Revised Regulations of Ontario, 1990 must be less than or equal to 25 per cent of the highest drug benefit price of the original product that was set out in the Formulary before its removal. 3. Despite paragraphs 1 and 2, for the purposes of setting the drug benefit price of an interchangeable product the executive officer may adjust the drug benefit price of the original product upon which the drug benefit price of the interchangeable product is based, having regard to the price of the original product in other provinces and territories, and the historical drug benefit price of the original product on the Formulary or as agreed to by the manufacturer and the executive officer under section 15 of this Regulation, but in doing so shall not change the actual drug benefit price of the original product on the Formulary where the original product is still listed. 4. In addition to the applicable conditions under paragraphs 1 and 2, if applicable, and if required by the executive officer, the manufacturer of the product shall enter into an agreement with the executive officer that specifies any volume discount or other amount that may be payable by the manufacturer to the Minister of Finance, and shall agree that the executive officer may make public the following information, and that information only, with respect to the agreement: i. The name of the manufacturer. ii. The subject-matter of the agreement. iii. The fact of entering into or terminating the agreement. O. Reg. 459/06, s. 6; O. Reg. 559/06, s. 1 (1); O. Reg. 355/08, s. 1 (1); O. Reg. 356/08, s. 2; O. Reg. 220/10, s. 2 (1-4); O. Reg. 115/15, s. 1 (1-4); O. Reg. 123/20, s. 1. (1.1) For the purposes of paragraphs 1 and 2 of subsection (1), all references to “25 per cent” shall be read as “35 per cent” in the case of a drug product that is not a solid dosage form. O. Reg. 220/10, s. 2 (5). (2) Paragraphs 1 and 2 of subsection (1) do not apply where there is evidence satisfactory to the executive officer that the product would be the only drug product of its type that has been proposed to be designated as interchangeable with an original drug product. O. Reg. 559/06, s. 1 (2); O. Reg. 220/10, s. 2 (6). (3) Where the circumstances described in subsection (2) exist, but subject to subsections (3.1), (3.2) and (3.3), the drug benefit price of the product proposed to the executive officer must be, (a) less than or equal to 75 per cent of the drug benefit price of the original product as set out in the Formulary on the date the product is first proposed for designation as a listed drug product; (b) if the drug benefit price of the original product has been reduced by more than 20 per cent in the 24-month period before the date on which the product is proposed for designation as a listed drug product, less than or equal to 75 per cent of the drug benefit price of the original product as set out in the Formulary immediately before the drug benefit price of the original product was first reduced; or (c) if the original product was but is no longer a listed drug product, less than or equal to 75 per cent of the highest drug benefit price of the original product that was set out in the Formulary before its removal. O. Reg. 115/15, s. 1 (5). (3.1) Where the circumstances described in subsection (2) exist and there is evidence satisfactory to the executive officer that there is another product listed, sold or available for sale that is interchangeable with the original product outside Ontario but within Canada, the references to “75 per cent” in subsection (3) shall be read as “50 per cent”. O. Reg. 115/15, s. 1 (5). (3.2) The references to “75 per cent” in subsection (3) shall be read as “85 per cent” where the circumstances described in subsection (2) exist and no agreement exists respecting the payment of a volume discount or other amount by the manufacturer in respect of the original product either, (a) between the executive officer and the manufacturer of the relevant original product; or (b) between the government or other appropriate authority in any province or territory outside Ontario but within Canada and the manufacturer of the relevant original product. O. Reg. 115/15, s. 1 (5). (3.3) The exceptions set out in subsections (2), (3), (3.1) and (3.2) do not apply where there is evidence satisfactory to the executive officer that there are two or more other products listed, sold or available for sale that are interchangeable with the original product outside Ontario but within Canada, in addition to the product proposed to be designated as interchangeable with the original product in Ontario and, for greater certainty, in those circumstances, the provisions of paragraphs 1 and 2 of subsection (1) apply. O. Reg. 115/15, s. 1 (5). (4) Paragraphs 1 and 2 of subsection (1) do not apply where, after designation of the proposed product, there would be only two drug products designated as interchangeable with an original drug product. O. Reg. 115/15, s. 1 (5). (4.1) Where the circumstances described in subsection (4) exist, but subject to subsection (4.2), the drug benefit price of a product proposed to the executive officer must be, (a) less than or equal to 50 per cent of the drug benefit price of the original product as set out in the Formulary on the date the product is first proposed for designation as a listed drug product; (b) if the drug benefit price of the original product has been reduced by more than 20 per cent in the 24-month period before the date on which the product is proposed for designation as a listed drug product, less than or equal to 50 per cent of the drug benefit price of the original product as set out in the Formulary immediately before the drug benefit price of the original product was first reduced; or (c) if the original product was but is no longer a listed drug product, less than or equal to 50 per cent of the highest drug benefit price of the original product that was set out in the Formulary before its removal. O. Reg. 115/15, s. 1 (5). (4.2) The exceptions set out in subsections (4) and (4.1) do not apply where there is evidence satisfactory to the executive officer that there is another product listed, sold or available for sale that is interchangeable with the original product outside Ontario but within Canada, in addition to the two that are or are proposed to be designated as interchangeable with the original product in Ontario and, for greater certainty, in those circumstances, the provisions of paragraphs 1 and 2 of subsection (1) apply. O. Reg. 115/15, s. 1 (5). (4.3) For greater certainty, nothing in this section shall be interpreted as limiting the authority of the executive officer to maintain an agreement described in subsection 12 (7) or paragraph 7 of subsection 12.1 (1) with the manufacturer of an original product. O. Reg. 115/15, s. 1 (5). (5) Upon the application of the manufacturer, the executive officer may re-designate a drug product that was designated on the Formulary before December 31, 2007, and whose designation was removed by either of the amendments to the Formulary known as Update 8 to Edition 40, effective January 15, 2008, or Update 8A to Edition 40, effective January 17, 2008, subject to the following: 1. The submission requirements set out in subsection 12 (1) shall be deemed to have been met with respect to the product. 2. The conditions for continued listing set out in section 12.1 must be met with respect to the product. 3. The criteria established by the executive officer under section 12.2 must be met with respect to the product. O. Reg. 355/08, s. 1 (2). (6) Revoked: O. Reg. 220/10, s. 2 (8). (7) Despite paragraphs 1 and 2 of subsection (1), during the three-month period provided for in paragraph 4 of subsection (8), the drug benefit price of a product that meets the conditions set out in subsection (8) must be less than or equal to 50 per cent of the drug benefit price of the original product on the date the product is first proposed for designation as a listed drug product. O. Reg. 220/10, s. 2 (9). (8) The conditions referred to in subsection (7) are the following: 1. The product is first proposed for designation as a listed drug product on or after April 1, 2012 and has not been designated as a listed drug product at any other time. 2. The manufacturer of the product has submitted evidence satisfactory to the executive officer that the manufacturer, or another manufacturer of a product that is interchangeable with the original product, has successfully challenged the patent of the original product with the result that the manufacturer’s product can be sold in Canada earlier than if the patent had expired or if the challenge had not been brought. 3. The manufacturer has not entered into any arrangement, other than a cross-licensing agreement, with the manufacturer of the original product with respect to the product that is proposed for designation as a listed drug product, including any first-to-market arrangement or delayed-entry arrangement. 4. The manufacturer agrees that the exception set out in subsection (7) no longer applies three months after the first product of any manufacturer that is interchangeable with the original product becomes a listed drug product, at which time the drug benefit price shall be as set out in subsection (1) or any other applicable provision of this Regulation. O. Reg. 220/10, s. 2 (9).
Read the GENERAL on e-Laws ↗

Made under Ontario Drug Benefit Act, R.S.O. 1990, c. O.10.